Compounds as CCR6 antagonists, their pharmaceutical compositions and uses
Compounds targeting CCR6 receptor with formula (I) address the lack of effective small molecule antagonists for IBD by offering potent CCR6 antagonism and improved therapeutic outcomes for autoimmune diseases.
JP2026517746APending Publication Date: 2026-06-02WUHAN LL SCI & TECH DEV CO LTD
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- WUHAN LL SCI & TECH DEV CO LTD
- Filing Date
- 2024-04-26
- Publication Date
- 2026-06-02
Smart Images
Figure 2026517746000001_ABST
Abstract
The present invention provides a compound represented by the following formula (I), its racemic mixture, stereoisomer, tautomer, nitrogen oxide, or pharmaceutically acceptable salt thereof. The compound has excellent CCR6 antagonistic activity as a CCR6 antagonist and also exhibits good pharmacokinetic and therapeutic properties. [Formula 1] JPEG2026517746000241.jpg33169
Need to check novelty before this filing date? Find Prior Art